Cargando…

Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1

BACKGROUND: The P.1 variant is a Variant of Concern announced by the WHO. The present work aimed to characterize the clinical features of pediatric patients with SARS-CoV-2 before and after the emergence of P.1. METHODS: This is a cohort study. Data of symptomatic patients younger than 18 years diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Char, Khong, Ka-Wah, Chan, Kwok-Hung, Lacerda, Marcus Vinicius Guimarães, Frank, Carlos Henrique Michiles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006205/
https://www.ncbi.nlm.nih.gov/pubmed/35418598
http://dx.doi.org/10.1038/s41390-022-02046-3
_version_ 1784686617844252672
author Leung, Char
Khong, Ka-Wah
Chan, Kwok-Hung
Lacerda, Marcus Vinicius Guimarães
Frank, Carlos Henrique Michiles
author_facet Leung, Char
Khong, Ka-Wah
Chan, Kwok-Hung
Lacerda, Marcus Vinicius Guimarães
Frank, Carlos Henrique Michiles
author_sort Leung, Char
collection PubMed
description BACKGROUND: The P.1 variant is a Variant of Concern announced by the WHO. The present work aimed to characterize the clinical features of pediatric patients with SARS-CoV-2 before and after the emergence of P.1. METHODS: This is a cohort study. Data of symptomatic patients younger than 18 years diagnosed with COVID-19 by PCR tests registered in Painel COVID-19 Amazonas were analyzed. RESULTS: A total of 4080 symptomatic pediatric patients were identified in the database between March 2020 and July 2021, of which 1654 were categorized as pre-P.1 and 978 as P.1-dominant cases, based on the prevalence of P.1 of >90% in the North Region, Brazil. Lower case-fatality rate was observed in non-infants infected during the P.1-dominant period (0.9% vs. 2.2%). In general, patients infected during the P.1-dominant period had less fever (70.8% vs. 74.2%) and less lower respiratory tract symptoms (respiratory distress: 11.8% vs. 18.9%, dyspnea: 27.9% vs. 34.5%) yet higher prevalence of neurological symptoms, headache for example (42.8% vs. 5.9%). CONCLUSIONS: The prevalence of symptoms of COVID-19 can differ across different periods of variant dominance. Lower prevalence of fever during the P.1-dominant period may reduce the effectiveness of symptom-based screening in public premises where laboratory diagnostic tests are not available. IMPACT: The prevalence rate of symptoms of SARS-CoV-2 infection can differ among different variants. The present work documents the difference in the clinical features of SARS-CoV-2 in patients aged below 18 years before and after the emergence of P.1, the first study of its kind. Unlike previous studies that focus solely on hospitalized cases, the present work considers both mild and severe cases. While non-infants had a lower fatality rate, lower prevalence of fever associated with the emergence of P.1 may reduce the effectiveness of symptom-based screening in public premises where laboratory diagnostic tests are not available.
format Online
Article
Text
id pubmed-9006205
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-90062052022-04-13 Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1 Leung, Char Khong, Ka-Wah Chan, Kwok-Hung Lacerda, Marcus Vinicius Guimarães Frank, Carlos Henrique Michiles Pediatr Res Clinical Research Article BACKGROUND: The P.1 variant is a Variant of Concern announced by the WHO. The present work aimed to characterize the clinical features of pediatric patients with SARS-CoV-2 before and after the emergence of P.1. METHODS: This is a cohort study. Data of symptomatic patients younger than 18 years diagnosed with COVID-19 by PCR tests registered in Painel COVID-19 Amazonas were analyzed. RESULTS: A total of 4080 symptomatic pediatric patients were identified in the database between March 2020 and July 2021, of which 1654 were categorized as pre-P.1 and 978 as P.1-dominant cases, based on the prevalence of P.1 of >90% in the North Region, Brazil. Lower case-fatality rate was observed in non-infants infected during the P.1-dominant period (0.9% vs. 2.2%). In general, patients infected during the P.1-dominant period had less fever (70.8% vs. 74.2%) and less lower respiratory tract symptoms (respiratory distress: 11.8% vs. 18.9%, dyspnea: 27.9% vs. 34.5%) yet higher prevalence of neurological symptoms, headache for example (42.8% vs. 5.9%). CONCLUSIONS: The prevalence of symptoms of COVID-19 can differ across different periods of variant dominance. Lower prevalence of fever during the P.1-dominant period may reduce the effectiveness of symptom-based screening in public premises where laboratory diagnostic tests are not available. IMPACT: The prevalence rate of symptoms of SARS-CoV-2 infection can differ among different variants. The present work documents the difference in the clinical features of SARS-CoV-2 in patients aged below 18 years before and after the emergence of P.1, the first study of its kind. Unlike previous studies that focus solely on hospitalized cases, the present work considers both mild and severe cases. While non-infants had a lower fatality rate, lower prevalence of fever associated with the emergence of P.1 may reduce the effectiveness of symptom-based screening in public premises where laboratory diagnostic tests are not available. Nature Publishing Group US 2022-04-13 2023 /pmc/articles/PMC9006205/ /pubmed/35418598 http://dx.doi.org/10.1038/s41390-022-02046-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Research Article
Leung, Char
Khong, Ka-Wah
Chan, Kwok-Hung
Lacerda, Marcus Vinicius Guimarães
Frank, Carlos Henrique Michiles
Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1
title Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1
title_full Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1
title_fullStr Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1
title_full_unstemmed Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1
title_short Difference in clinical features of SARS-CoV-2 in pediatric patients before and after emergence of P.1
title_sort difference in clinical features of sars-cov-2 in pediatric patients before and after emergence of p.1
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006205/
https://www.ncbi.nlm.nih.gov/pubmed/35418598
http://dx.doi.org/10.1038/s41390-022-02046-3
work_keys_str_mv AT leungchar differenceinclinicalfeaturesofsarscov2inpediatricpatientsbeforeandafteremergenceofp1
AT khongkawah differenceinclinicalfeaturesofsarscov2inpediatricpatientsbeforeandafteremergenceofp1
AT chankwokhung differenceinclinicalfeaturesofsarscov2inpediatricpatientsbeforeandafteremergenceofp1
AT lacerdamarcusviniciusguimaraes differenceinclinicalfeaturesofsarscov2inpediatricpatientsbeforeandafteremergenceofp1
AT frankcarloshenriquemichiles differenceinclinicalfeaturesofsarscov2inpediatricpatientsbeforeandafteremergenceofp1